Axsome Therapeutics, Inc. (LON:0HKF)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 8.54B +117.2% |
| Revenue (ttm) | 536.35M +63.9% |
| Net Income | -142.60M |
| EPS | -2.83 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 252 |
| Average Volume | 622 |
| Open | 225.00 |
| Previous Close | 224.22 |
| Day's Range | 223.00 - 231.05 |
| 52-Week Range | 96.87 - 232.58 |
| Beta | 0.59 |
| RSI | 61.60 |
| Earnings Date | May 4, 2026 |
About Axsome Therapeutics
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago... [Read more]
Financial Performance
In 2025, Axsome Therapeutics's revenue was $638.50 million, an increase of 65.55% compared to the previous year's $385.69 million. Losses were -$183.17 million, -36.22% less than in 2024.
Financial numbers in USD Financial StatementsNews
Axsome Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
AUVELITY's new ADA indication and strong MDD performance are driving a major sales force expansion and broader market access, with robust payer coverage and minimal patient out-of-pocket costs. Growth targets remain ambitious, supported by disciplined DTC investment and a promising pipeline including SYMBRAVO and SUNOSI.
Axsome Therapeutics Recognizes Mental Health Month
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann...
Axsome Therapeutics price target lowered to $280 from $281 at Deutsche Bank
Deutsche Bank analyst David Hoang lowered the firm’s price target on Axsome Therapeutics (AXSM) to $280 from $281 and keeps a Buy rating on the shares.
Axsome Therapeutics price target raised to $267 from $255 at Needham
Needham raised the firm’s price target on Axsome Therapeutics (AXSM) to $267 from $255 and keeps a Buy rating on the shares.
Axsome Therapeutics price target raised to $242 from $217 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Axsome Therapeutics (AXSM) to $242 from $217 and keeps an Equal Weight rating on the shares. The firm notes that its updated…
Axsome Therapeutics price target raised to $302 from $242 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on Axsome Therapeutics (AXSM) to $302 from $242 and keeps an Outperform rating on the shares after its Q1 results.
Axsome Therapeutics price target raised to $310 from $228 at Mizuho
Mizuho raised the firm’s price target on Axsome Therapeutics (AXSM) to $310 from $228 and keeps an Outperform rating on the shares.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann...
Axsome Therapeutics price target raised to $246 from $241 at Baird
Baird analyst Brian Skorney raised the firm’s price target on Axsome Therapeutics (AXSM) to $246 from $241 and keeps an Outperform rating on the shares. The firm updated its model…
Axsome Therapeutics price target raised to $290 from $270 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $290 from $270 and keeps a Buy rating on the shares. The firm cites “increased enthusiasm” for Auvelity’s…
Axsome Therapeutics price target raised to $276 from $239 at BofA
BofA analyst Jason Gerberry raised the firm’s price target on Axsome Therapeutics (AXSM) to $276 from $239 and keeps a Buy rating on the shares. The company’s Q1 report “crystallizes…
Axsome Therapeutics price target raised to $280 from $250 at Oppenheimer
Oppenheimer raised the firm’s price target on Axsome Therapeutics (AXSM) to $280 from $250 and keeps an Outperform rating on the shares. The firm views Axsome’s Q1 results are emboldening…
Axsome Therapeutics management to meet with Needham
Meeting to be held in New York on May 5 hosted by Needham.
Axsome Therapeutics management to meet with Piper Sandler
Meeting to be held in New York on May 7 hosted by Piper Sandler.
Axsome Therapeutics price target raised to $260 from $245 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Axsome Therapeutics (AXSM) to $260 from $245 and keeps a Buy rating on the shares, citing continued strong product performance,…
Axsome Therapeutics price target raised to $258 from $223 at Piper Sandler
Piper Sandler raised the firm’s price target on Axsome Therapeutics (AXSM) to $258 from $223 and keeps an Overweight rating on the shares.
Axsome Therapeutics price target raised to $272 from $234 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Axsome Therapeutics (AXSM) to $272 from $234 and keeps an Overweight rating on the shares.
Axsome Therapeutics price target raised to $275 from $245 at Jefferies
Jefferies analyst Andrew Tsai raised the firm’s price target on Axsome Therapeutics (AXSM) to $275 from $245 and keeps a Buy rating on the shares. Auvelity’s Q1 sales of $153M…
Axsome Therapeutics price target raised to $281 from $245 at Deutsche Bank
Deutsche Bank analyst David Hoang raised the firm’s price target on Axsome Therapeutics (AXSM) to $281 from $245 and keeps a Buy rating on the shares. The firm is bullish…
Axsome Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw 57% revenue growth, FDA approval of AUVELITY for Alzheimer's agitation, and expanded commercial infrastructure. Updated peak sales guidance for AUVELITY is at least $8 billion annually, with strong cash reserves supporting ongoing R&D and launches.
Axsome Therapeutics reports Q1 EPS ($1.26), consensus (86c)
Reports Q1 revenue $191.2M, consensus $190.69M. “Axsome had a tremendous start to 2026. Our commercial business delivered robust year-over-year growth in the first quarter, Auvelity was approved by th...
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Total 1Q 2026 net product revenue of $191.2 million, representing 57% year-over-year growth AUVELITY ® 1Q 2026 net product sales of $153.2 million, representing 59% year-over-year growth SUNOSI ® 1Q 2...
Axsome Therapeutics price target raised to $270 from $250 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Axsome Therapeutics (AXSM) to $270 from $250 and keeps a Buy rating on the shares. The firm cites the…
Axsome Therapeutics price target raised to $255 from $215 at TD Cowen
TD Cowen raised the firm’s price target on Axsome Therapeutics (AXSM) to $255 from $215 and keeps a Buy rating on the shares. The firm’s survey work suggests that Alzheimer’s…
Axsome Therapeutics Transcript: FDA announcement
FDA approved AUVELITY as the first non-antipsychotic for agitation in Alzheimer's dementia, based on robust efficacy and safety data. Launch is set for June with strong insurance coverage and high anticipated compliance, addressing a major unmet need for millions of patients and caregivers.